In this issue of Molecular Medicine, Irvine et al.(1) expound upon the application of
molecular biology in clinical medicine and the enabling of targeted interactions at a …

Positron emission tomography (PET) allows non-invasive assessment of physiological,
metabolic and molecular processes in humans and animals in vivo. Advances in detector …

CNS drug candidates fail approval in over 90% of the cases due to poor targeting, lack of
efficacy, and/or unacceptable side effects. In vivo imaging offers a pathway to derisk drug …

A new era of discovery and medical advances began on June 26, 2000, with the completion
of the first map of the human genome (1). Although much work remains to complete a refined …

The role of molecular neuroimaging techniques is increasing in the understanding of
pathophysiological mechanism of diseases. To date, positron emission tomography is the …

PET-based molecular-genetic imaging is part of a larger base of three imaging technologies
(nuclear, magnetic resonance, and optical) incorporating methods that are established in …

Molecular imaging aims to assess non-invasively disease-specific biological and molecular
processes in animal models and humans in vivo. Apart from precise anatomical localisation …

In order for personalized medicine to become a clinical reality a number of hurdles, both
technological and regulatory in nature, need to be addressed. Our ability to image biological …

The use of molecular imaging techniques in the central nervous system (CNS) has a rich
history. Most of the important developments in imaging—such as computed tomography …

PET, along with an array of radiotracers, is used to study many physiologic and pathologic
states throughout the body. Its applications in studying the brain, as a research and as a …